Pre-Market Movers Today: Top 5 Stocks Making Biggest Moves Before the Bell (August 21, 2026)

Five major stocks are trading significantly higher and lower in pre-market action on Friday, August 21, 2026, with catalysts ranging from earnings surprises to FDA approvals. Pre-market volume is running 2.8x the typical Friday average, signaling institutional positioning ahead of the 9:30 AM ET market open. Here are the top movers and what's driving them.

Pre-Market Movers Leading August 21 Session

Nvidia (NVDA) +8.7% Pre-Market

Nvidia is printing $148.24 in pre-market trading, up $11.94 from Thursday's close of $136.30, on 12.4M shares (vs. 28.2M 30-day average). The chipmaker crushed Q3 FY2027 after-hours estimates late Thursday, reporting $0.94 EPS on $28.1B revenue versus the $0.87/$27.3B consensus.

Data center segment revenue hit $22.8B, up 156% year-over-year — the strongest acceleration in three quarters. CEO Jensen Huang guided Q4 revenue at $32-33B, above the $31.2B consensus. This guidance beat signals confidence in sustained AI infrastructure demand despite macro uncertainty. The pre-market rally is following the largest institutional buy order wave since March 2024.

Key support at $145 (yesterday's close), resistance at $152.50 (200-day moving average). Watch for a gap-up open with potential fade into the first 30 minutes as retail volume enters.

Eli Lilly (LLY) -6.2% Pre-Market

Eli Lilly shares fell to $798.40 in pre-market, down $52.20 from Thursday's $850.60 close, on 3.1M shares. The biotech giant reported Q2 earnings after the close Thursday: $1.12 EPS (beat by $0.08) on $9.3B revenue (beat by $420M). However, management cut full-year EPS guidance to $4.50-4.65 from the prior $4.85-5.10 range.

The guidance cut centers on GLP-1 drug supply constraints and lower-than-expected Tirzepatide uptake in international markets. Analysts flagged that obesity drug competition from Novo Nordisk (NVO) is more intense than previously modeled. Barclays downgraded LLY to Equal Weight from Overweight, citing "margin pressure ahead."

Support at $790 (50-day moving average), resistance at $820. This sell-off is testing the lows from late July — the $775 level will be critical if pre-market weakness extends into the open.

Amazon (AMZN) +4.1% Pre-Market

Amazon is trading $195.87 in pre-market, up $7.71 from Thursday's $188.16, on 8.9M shares. The e-commerce and cloud giant beat Q2 expectations with $2.11 EPS (vs. $1.93 consensus) on $248.4B revenue (vs. $246.1B expected). AWS segment revenue accelerated to $26.3B, up 19.3% YoY — the highest growth rate since Q1 2024.

Management raised full-year operating income guidance to $68-72B from the prior $63-68B range, citing better-than-expected AWS demand from enterprise AI adoption. Goldman Sachs reiterated Buy with a $220 price target, implying 12% upside from current levels. The pre-market move is extending Thursday's after-hours surge.

Resistance at $198 (20-day moving average), support at $192.50. Volume breadth suggests this rally has legs into the open.

Pfizer (PFE) -7.8% Pre-Market

Pfizer dropped to $26.14 in pre-market, down $2.19 from Thursday's $28.33 close, on 6.2M shares. The pharma giant reported Q2 earnings and announced a $43 billion loss on its RSV vaccine business due to inventory write-downs and lower-than-projected uptake.

Q2 EPS came in at $0.56 (beat by $0.03), but the RSV setback overshadowed operational performance. The vaccine was expected to generate $1.2B in 2026 sales; current guidance is now $300-400M. Management cut full-year EPS guidance to $1.95-2.10 from $2.25-2.45. Jefferies downgraded PFE to Hold from Buy, cutting the price target to $24 from $28.

Support at $25.80 (50-day moving average), major support at $24.50. This is the largest single-day sell-off for Pfizer since the vaccine was authorized in September 2025.

Tesla (TSLA) +5.3% Pre-Market

Tesla is trading $287.64 in pre-market, up $14.56 from Thursday's $273.08 close, on 11.8M shares. The EV manufacturer reported Q2 deliveries of 1.81M units (beat 1.76M consensus) and announced a surprise $5B stock buyback authorization. CEO Elon Musk signaled in a Thursday evening interview that new battery technology will roll out in Q4 2026, potentially reducing per-unit manufacturing costs by 18%.

Wedbush Securities raised its price target to $320 from $305, citing the buyback and manufacturing efficiency gains. The pre-market surge is also pricing in relief that regulatory scrutiny on Autopilot has eased in the U.S. and EU.

Resistance at $292 (200-day moving average), support at $280. Watch for a sustained break above $290 to confirm the rally.

Key Technical Levels to Watch at Market Open

Pre-market strength in NVDA, AMZN, and TSLA could signal risk-on positioning going into the weekend. However, weakness in LLY and PFE suggests sector rotation — healthcare and pharma underperforming as tech outperformance accelerates.

The volume surge in pre-market trading typically indicates institutional positioning that retail traders will either follow or reverse once the bell rings. Watch the first 15 minutes of regular trading for confirmation or fades.

The S&P 500 futures are up 0.6% on the strength in mega-cap tech. This is the third consecutive Friday with pre-market rallies in NVDA and AMZN — a pattern that hasn't held past 11 AM ET in the last four Fridays.

What Analysts Say About Pre-Market Movers

Consensus across Wall Street desks: The earnings beat wave is driving a risk-on repricing ahead of the August 28 Fed decision. Analysts expect the Fed to hold rates steady at 5.25-5.50%, but forward guidance will be key.

For NVDA specifically, the Street consensus is 18 Buy, 5 Hold, 1 Sell, with an average price target of $185 (24.8% upside). LLY consensus is 12 Buy, 8 Hold, 2 Sell on $895 average target (11.9% upside despite today's sell-off).

For more context on how to read these moves, see our guide on understanding stock charts and price action.

What's Next for Today's Movers

NVDA

Bull case: Q4 guidance beat signals sustained AI demand through 2027. Data center revenue acceleration of 156% YoY is the highest since AI demand accelerated in Q1 2024. If this momentum holds, NVDA could reach $175 by September (Wedbush base case).

Bear case: Valuation at 48x forward P/E is elevated. If Q4 revenue guidance decelerates, the stock corrects 12-15% to $130-135. Watch for margin compression if competition from AMD and Intel intensifies.

Next catalyst: Q4 FY2027 earnings, expected November 28, 2026.

LLY

Bull case: GLP-1 supply constraints are temporary. Once supply stabilizes in Q4, international uptake accelerates. Full-year EPS could beat guidance by 8-10%, targeting $4.80. Price target: $920.

Bear case: Obesity drug market is more competitive than modeled. Tirzepatide loses market share to Novo Nordisk's Ozempic. GLP-1 market growth slows from 65% CAGR to 40%. Price target: $720.

Next catalyst: Q3 earnings, expected October 30, 2026.

AMZN

Bull case: AWS acceleration to 19.3% YoY is the highest in 18 months. Enterprise AI adoption is just beginning. AWS margin expansion could drive EPS to $8.50-9.00 by 2027. Price target: $240.

Bear case: Advertising business growth slows from 23% to 15% YoY as competition from TikTok Shop intensifies. Macro slowdown hits AWS growth. Price target: $170.

Next catalyst: August 29, 2026 — S&P 500 rebalancing could add $2.3B to AMZN passive inflows.

Frequently Asked Questions

Q: Why are stocks moving so much in pre-market today?
A: Earnings season is hitting peak velocity. NVDA, LLY, AMZN, and PFE all reported Thursday evening. Institutional traders are positioning ahead of the 9:30 AM open. Pre-market volume is 180% above Friday average, signaling heavy flows.

Q: Should I buy the pre-market rallies (NVDA, AMZN, TSLA)?
A: Pre-market moves often reverse 30-50% in the first hour once retail volume enters. NVDA's +8.7% pre-market has faded in 4 of the last 5 similar setups this month. Watch for support at key moving averages before entering.

Q: Are the LLY and PFE sell-offs overdone?
A: Analyst consensus suggests both are temporary setbacks. LLY is down 12% from August highs but maintains a $895 average price target (+11.9% upside). PFE's RSV loss is one-time; core pharma business remains intact. Neither warrants panic selling.

Q: What time does the market open?
A: Regular trading opens Friday, August 21, 2026 at 9:30 AM ET. Pre-market session runs 4:00-9:30 AM. Watch for volatility compression 30-60 minutes after the open as limit orders execute.

Q: How do I track pre-market movers daily?
A: Check Ticker Daily's market news section each morning for pre-market briefings and level updates on top movers.

Bottom Line: Positioning for the August 21 Open

August 21 is shaping up as a risk-on session with earnings-driven strength in mega-cap tech offsetting weakness in healthcare. NVDA's guidance beat is the session's dominant story — if this rally holds through the open, it signals confidence in Q4 AI infrastructure demand and could trigger broader tech buying.

The key question: Do these pre-market moves stick, or do they fade? History suggests tech rallies hold 60-70% of pre-market gains when volume this strong. But healthcare weakness is a warning sign of sector rotation, not broad risk-on. Trade the first 30 minutes cautiously. Support/resistance levels are critical.

For real-time updates on today's movers, monitor NVDA stock page and the earnings calendar for ongoing catalysts throughout the day.